Genes shape GLP‑1 results

Glucagon-like peptide 1 drugs work by copying a gut hormone your body already uses after a meal, so your stomach empties more slowly and your brain gets a stronger “you’ve had enough” signal. Semaglutide is one of those drugs, and tirzepatide goes a step further by also acting on a second gut-hormone pathway called gastric inhibitory polypeptide. (nature.com) That sounds simple, but the results are not. In the new Nature study, researchers looked at 27,885 people who reported taking these drugs and found big person-to-person differences in both weight loss and side effects. (nature.com) To hunt for an explanation, they used a genome-wide association study, which is basically a giant scan across millions of DNA spelling differences to see which ones track with a trait. Here the traits were weight loss and nausea or vomiting after starting a glucagon-like peptide 1 drug. (nature.com) The clearest signal landed on GLP1R, the gene that builds the receptor semaglutide is designed to hit. One missense variant in GLP1R, meaning a one-letter DNA change that alters the protein itself, was linked to an extra 0.76 kilograms of weight loss for each copy of that variant. (nature.com) That is the neat part of this paper: the strongest genetic clue showed up in the drug’s actual lock, not in some distant pathway. Ruth Loos wrote in Nature’s news analysis that this gives direct evidence that variation in the target genes helps explain why two people on the same medicine can get different results. (nature.com) The side-effect story pointed to the same biology. Variants in GLP1R and in GIPR, the gene for the gastric inhibitory polypeptide receptor, were associated with nausea or vomiting during treatment. (nature.com) The GIPR signal came with an important twist. It showed up only in people taking tirzepatide, which makes sense because tirzepatide targets both the glucagon-like peptide 1 receptor and the gastric inhibitory polypeptide receptor, while semaglutide targets only the first one. (nature.com) The researchers did not find a single “good responder” gene that explains everything. Scientific American noted that the variants help explain only part of the spread in outcomes, which means dose, diet, other biology, and behavior still matter a lot. (scientificamerican.com) They also built a broader response model that could sort people by likely benefit and side-effect risk. The paper says that kind of stratification is a step toward precision medicine, where a prescription is matched to the patient instead of handed out as if everybody’s body reads the same instruction manual. (nature.com) This is not a home DNA test telling you whether to start Ozempic or Zepbound tomorrow. It is an early map of why these drugs can feel almost custom-made for one person and miserable or underwhelming for another, and it points straight at the hormone receptors the drugs were built to use. (nature.com)